Bristol Myers touts early social and environmental progress among achievements in latest ESG report

A boost for di­ver­si­ty in clin­i­cal tri­als and an ear­li­er-than-ex­pect­ed $1 bil­lion spend with mi­nor­i­ty-owned busi­ness­es are some of the high­lights in Bris­tol My­ers Squibb’s lat­est en­vi­ron­men­tal, so­cial, and gov­er­nance (ESG) re­port.

Bris­tol My­ers re­port­ed that it placed 58% of its clin­i­cal tri­al sites in “some of the most racial­ly and eth­ni­cal­ly di­verse metro re­gions” in the US, which is ahead of its 25% goal and three years ear­li­er than pro­ject­ed. An­oth­er ear­ly mile­stone is the $1 bil­lion Bris­tol My­ers has now spent with glob­al sup­pli­er com­pa­nies owned by peo­ple from un­der­rep­re­sent­ed groups, women, vet­er­ans, LGBTQ+ peo­ple and peo­ple with dis­abil­i­ties — ahead of its ini­tial 2025 time­line for that achieve­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.